Translating science
into innovative
diagnostic solutions

Latest news

Clarifi COVID-19 Testing

Quadrant Biosciences has received an Emergency Use Authorization (EUA) from the FDA for the Clarifi COVID-19 Test Kit by SUNY Upstate Medical and Quadrant Biosciences, a saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.

The Clarifi COVID-19 Test, developed in partnership with SUNY Upstate Medical University,  leverages Quadrant Biosciences’ established expertise in RNA-based diagnostics. The non-invasive, and easy to administer, saliva swab test determines the presence or absence of SARS-CoV-2 viral RNA. The Clarifi COVID-19 Test contains a saliva collection swab and the reagents needed to run the analysis, and will be immediately available for use by high-complexity clinical laboratories serving patients through physicians’ offices, urgent care clinics and hospitals.

Click on the link to read the full press release:

Wastewater surveillance

Our company, in collaboration with Syracuse University, SUNY Upstate Medical University, SUNY College of Environmental and Forestry, and global engineering firm Arcadis, is analyzing wastewater across New York State for the COVID-19 virus. 

Wastewater surveillance acts as an early warning system for COVID-19 by detecting the presence of viral RNA shed into the sewer systems. Our analysis of wastewater samples will provide local health officials and policymakers with early indications and information regarding the presence and preponderance of COVID-19 infections in these communities.

Click on these links to recent press about this collaborative project:

More news

Our aim is to develop solutions for important global health issues

Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary  advancements in the early detection of autism spectrum disorder, Parkinson’s disease and mTBI,  through the application of the Clarifi™  epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. Clarifi ASD, an autism diagnostic aid, is the first product to launch commercially from this platform. Clarifi ASD is now available through prescription; details on how to obtain testing are available on Clarifi’s website

Development, Solutions, Global Health Issues, Groundbreaking
Quadrant Biosciences, biotech, Development, Global Health Issues, Solutions, Diagnostic, Early Detection
Quadrant Biosciences, Development, Global Health Issues, Solutions, Diagnostic, Early Detection

Be part of a study

Be part of a study

Autism research study

Children ages 18 months to 48 months with an autism diagnosis, developmental delays, or a suspicion of autism are eligible.

Parkinson’s Study

Help us learn how to better diagnose Parkinson’s Disease at an earlier stage.